Dr Ros Eeles email@example.com
Institute of Cancer Research
Investigation is taking place into the genetic predisposition to
prostate cancer. The research includes the identification of high
and low penetrance genes and the role of gene-environment interactions.
The biggest, and oldest study began in 1992 and involves a nationwide
programme to identify families with a familial susceptibility to
prostate cancer, especially those under 60 years of age at diagnosis
and/or families with three or more prostate cancer cases.
The aim is to recruit 6000 patients with prostate cancer
before 2010. To date there have been 4000 patients
identified in the UK that are eligible for the study, with
2600 patients fully consented and participating already.
Currently, there are 220 collaborators including
urologists, oncologists, geneticists, and research nurses
across the UK who refer patients into the study to help
achieve the project targets.
The research team also collaborates with a number of other centres around the
UK. Links have been established with Nottingham
University, to conduct a gene-environment interaction study,
coordinated by Dr Ken Muir and Dr Tim Key. This project is funded
by the Prostate Cancer Charitable Trust. Another study, situated
at the Royal Marsden Hospital & the Institute of Cancer Research
and funded by the Prostate Research Charity UK, is looking at the
effects of irradiation in men with a genetic predisposition to prostate
cancer. In addition, the research team is studying the effects of
the genetic make-up of the immune system with Dr Martin Howell at
Southampton, funded by the Wessex Cancer Charity.
Future plans for the team are likely to include the use of
the human genome sequence to identify prostate cancer
genes, as well as identification of more patients via the
A breakdown of the 2600 patients that have consented to the
study, June 2002:
PRM - 1862 Royal Marsden prostate cancer patients identified.
This represents the systematic series of the study (target 4000).
PRS - 276 patients identified with a family history of prostate
cancer e.g. siblings, fathers, grandfathers and uncles etc. (target
PRT - 46 patients identified from the Thames Cancer Registry.
PRY - 416 patients identified that are all <60yrs at diagnosis
i.e. young patients (target 1000).
Explanation of the graphs.
Graph 1 - RMH (PRM) Patients Consented by Year of Consent.
The top graph demonstrates a graphical representation of the average
number of RMH patients that are consenting and entering the familial
prostate cancer study every week (~9). The lower graph shows the
average number of RMH patients that have entered the study each
year since the study begun, with a target of 445 for 2002.
Graph 2 - RMH (PRM) Patients Consented Each Week,
since 2001, on a Cumulative Basis.
This graph demonstrates the number of patients that have consented
each week, over the last 18 months, comparing figures week-by-week
for 2001 and 2002.
1) Kote-Jarai Z, Easton D, Edwards SM, Jefferies S, Jackson
RA, Ardern-Jones A, Murkin A, Durocher F, Dearnaley DP,
Singh R, Shearer R, Kirby R, The CRC/BPG UK Familial
Prostate Cancer Study Collaborators, Houlston R, Eeles RA.
(2001). Relationship between Glutathione S-Transferase M1,
P1 and T1 polymorphisms and early onset prostate cancer.
Pharmacogenetics 11: 325-330.
2) Sarah L. McCarron, Stephen Edwards, Philip R. Evans, Roz
Gibbs, David P. Dearnaley, Anna Dowe, Christine Southgate,
The Cancer Research Campaign/British Prostate Group United
Kingdom Familial Prostate Cancer Study Collaborators,
Douglas F. Easton, Rosalind A. Eeles and W. Martin Howell.
Influence of Cytokine Gene Polymorphisms on the Development
of Prostate Cancer. Cancer Res. 2002 62: 3369-3372.
3) Z Kote-Jarai, F Durocher, S M Edwards, R Hamoudi, R A
Jackson, A Ardern-Jones, A Murkin, D P Dearnaley, R Kirby,
R Houlston, D F Easton, R Eeles and the CRC?BPG UK Familial
Prostate Cancer Collaborators. Association between the GCG
polymorphism of the selenium dependent GPX1 gene and the
risk of young onset prostate cancer. Prostate Cancer and
Prostatic Diseases (2002) 5, No 3, 189-192.
4) J C Meitz, S M Edwards, D F Easton, A Murkin, A
Ardern-Jones, R A Jackson, S Williams, D P Dearnaley, M R
Stratton, R S Houlston. The Cancer Research UK/BPG UK
Familial Prostate Cancer Study Collaborators and R A Eeles.
HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis
by age of onset of disease. British Journal of Cancer 2002
87, No. 8, 905 - 908.